$13B acquisition deal + 10 more major updates...👇
Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence
🎯 → Approvals
🔬 → New data
🤝 → M&A activity
Bristol Myers Squibb
🎯 EC approved Reblozyl® (luspatercept) to include first-line treatment of transfusion-dependent anemia in adults with LR-MDS.
🎯Received FDA approval for CAR T cell therapy Abecma treating triple-class exposed relapsed or refractory multiple myeloma after two prior lines of therapy.
Vanda Pharmaceuticals
🎯FDA approved Fanapt® (iloperidone) acute treatment for bipolar I disorder.
Ocugen
🔬 Received positive recommendation from DSMB and will initiate medium-dose cohort for OCU410 treating geographic atrophy.
Biora Therapeutics
🔬 Reported interim data for BT-600, advancing NaviCap™ platform development.
Cytokinetics
🔬 48-Week data reported from the FOREST-HCM trial of Aficamten.
Candel Therapeutics
🔬 Interim Ph2 data reported showing increased overall survival of 28.8 months VS 12.5 months in the control group of CAN-2409 in non-metastatic pancreatic cancer.
CureVac & GSK
🔬 Ph2 interim data reported from the seasonal influenza vaccine development program in collaboration with GSK.
Achilles Therapeutics
🔬 Reported Ph1/2a interim data from the clonal neoantigen reactive T-Cells in advanced NSCLC and melanoma including first patients dosed with enhanced host conditioning
Johnson & Johnson & Shockwave Medical
🤝 To acquire Shockwave Medical for $13.1B.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
April 1-5, 2024
Article History:
RF, DV (04/05/24)
Comentários